The company develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Akebia has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.
Cyborg Score Rationale
Revenue declined 17.7% year-over-year in 2024 to $160.2M, while net losses increased 33.7% to $69.4M. However, analysts rate AKBA as "Strong Buy" with a 12-month target of $6.25, suggesting 303% upside potential.
Top Insights
Vafseo (vadadustat) is FDA-approved for treating anemia due to chronic kidney disease in adult patients on dialysis for at least three months.
Company is developing AKB-9090 for cardiac surgery-related acute kidney injury and AKB-10108 for retinopathy of prematurity in neonates.
Investors focus on Vafseo adoption among dialysis organizations, Auryxia performance, and progress of VOICE and VOCAL Phase 2 studies.
Short interest stands at 36.9M shares (14.9% of float), up 122.8% over 12 months, indicating notable bearish positioning.
Named Competitors
Veltassa — Potassium binder for hyperkalemia in CKD
Venofer — Intravenous iron supplement for anemia in CKD
Esperoct — ETC-1002 therapy for lipid management
Recent Developments
(February 2026) Akebia price target lowered to $4 from $5 at BTIG
(January 2026) Company announces corporate updates and 2026 pipeline outlook
(December 2025) Akebia acquires global rights to ADX-097 complement inhibitor from Q32 Bio
Open the full interactive Akebia Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.